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COMMENT
FROM HERBAL PROZAC TO MARK
MCGWIRE'S TONIC: HOW THE DIETARY
SUPPLEMENT HEALTH AND EDUCATION ACT




St. John's Wort doth charm all witches away,
If gathered on the saint's holy day.
Any devils and witches have no power to harm
Those that gather the plant for a charm.
Rub the lintels with that red juicy flower;
No thunder nor tempest will then have the power
To hurt or hinder your house; and bind
Round your neck a charm of similar kind.'
Walk into any health food store or pharmacy and you will find rows
of vitamins and minerals to supplement your daily diet. Consumers are
faced with new lines of herbs and supplements making health related
claims such as "feel good mentally," "relieve anxiety," and "put on 10
pounds of muscle in three weeks while adding 20 pounds to your
bench press,"2 none of which require a prescription. Because these
* B.A. Catholic University of America, 1997; J.D. Candidate 2000,
Catholic University of America, Columbus School of Law. The author
would like to thank her family, friends, the editors of The Journal and Fre-
derick Degnan for their guidance and support.
1. Poem c.1400A.D., from St. John's Wort, Avery 1998, cited in Michael
T. Murphy, Battling the Blues with St. John's Wort, BETTER NUTRITION, Feb.
1998, at 14.
2. Marion Jones, Mark McGwire's Muscle Pills: Supplements or Ster-
oids? (last modified Aug. 26, 1998) <http://www.foxnews.com/js_index.
sml?content=/health/082698/sluggerdrugs.sml>.
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products are labeled and marketed as "dietary supplements," there are
no established standards or manufacturing controls for them, nor stan-
dards by which to judge their effectiveness or their safety. 3 Yet, open
almost any magazine or turn on the news, and the benefits of these
supplements are praised.4
Supplement alternatives to established medicines are used by ap-
proximately one-third of the U.S. population. Herbal supplements are
the most common,6 and their usage has increased since the passage of
the Dietary Supplement Health and Education Act of 1994 (DSHEA).7
In 1996 alone, consumers spent over $6.5 billion on dietary supple-
ments.8 In the past, these products were found mainly in health food
stores and marketed principally to adults, but now they are available
from a number of different sources. 9 Dietary supplements are often
introduced as offering a health benefit, but stop short of making direct
therapeutic claims. Many consumers spend their money without
3. See Marian Burros, Eating Well: Dietary Supplements: Let the Buyer
Beware, N.Y. TIMES, Oct. 16, 1991, at Cl; see also, Science Friction: Main-
stream Medicine Faces a Challenge From Alternative Practices. A debate be-
tween Arnold S. Relman and Andrew Weil, WASH. POST, May 25, 1999, §HM
(Health), at I I [hereinafter Science Friction].
4. See Herbal Supplements, What You Don't Know Can Hurt You,
GLAMOUR, Oct. 1998, at 314; see also Christine Gorman, Is it Good Medi-
cine?, TIME, Nov. 23, 1998, at 69.
5. See NAT'L INST. OF HEALTH/NAT'L INST. OF ENVTL. HEALTH SCI.
INT'L WORKSHOP TO EVALUATE RESEARCH NEEDS ON THE USE AND SAFETY
OF MEDICINAL HERBS, CONFERENCE SUMMARY 1, September 23-24, 1998,
Raleigh, North Carolina [hereinafter NIH RESEARCH WORKSHOP].
6. See Paula Kurtzweil, US. Food and Drug Administration, FDA Con-
sumer Guide to Daily Supplements (visited Oct. 20, 1998) <http://vm.cfsan.
fda.gov/-dms/fdsupp.html>. Research shows that half of the adult U.S.
population use daily supplements. See id.
7. See NIH Research Workshop, supra note 5, at 1; see also Pub. L. No.
103-417, 108 Stat. 4325 (1994).
8. See Kurtzweil, supra note 6 (citing Packaged Facts Inc., a market re-
search firm.in New York City).
9. See Statement by Jane E. Henney, M.D., Commissioner Before the
House Comm. on Gov't Reform, U.S. House of Rep. (visited Mar. 5, 1999)
<http://vm.cfsan.fda.gov/-lrd/sthenney.html> at 4. See also Science Friction,
supra note 3.
From Herbal Prozac to Mark McGwire's Tonic
knowing if these products are safe, if the claims can be trusted, or if
they will actually help. In short, consumers do not know whether they
are just throwing their money away on the latest fad.
The Food and Drug Administration's (FDA) mission includes pro-
tecting consumers from adulterated and misbranded foods, drugs, de-
vices and cosmetics.' o This mission remains the same even though
federal laws changed the way the FDA evaluates and regulates these
products."I "Foods" and "drugs" are two different categories under the
federal Food, Drug and Cosmetic Act (FDCA). 12 "New drugs" must
undergo rigorous clinical testing for effectiveness and safety, 13 while
both foods and drugs are policed to insure that they are not adulterated
and are correctly labeled. 14 If they make a "health claim,"' 5 that claim
must be substantiated and pre-approved by the FDA.'
6
Although Congress declared vitamins, minerals, and other forms of
dietary supplements as a distinct category of foods in 1976,'7 the FDA
has always successfully controlled the more aggressive marketing of
these products. This regulation, under the rubrics of food and drugs,
dramatically limited the types of claims products could make in the
absence of strong, scientific proof.'8 As a result of lobbying efforts to
prevent the FDA from having this level of control over supplements,
Congress passed the DSHEA in 1994.'9 This opened the floodgates for
10. See RICHARD MERRILL & PETER B. HUTT, FOOD AND DRUG LAW
CASES AND MATERIALS 3-4 (1980).
11. See infra Part II.B. and accompanying notes.
12. 21 U.S.C. § 321 etseq. (1998).
13. See 21 U.S.C. §403 (1998).
14. See 21 U.S.C. § 352 (1998). The Nutritional Labeling and Education
Act now requires that food labels contain nutritional information. See Pub.
L. No. 101-535, 104 Stat. 2353 (1990).
15. The Act defines a health claim as one that suggests the product to be
useful for the "cure, mitigation, treatment or prevention" of disease. See 21
U.S.C. § 321(g) (1998).
16. See 21 U.S.C. § 342 (1998).
17. See 21 U.S.C. § 321(ff) (1998).
18. See infra Part II.A. and accompanying notes.
19. See Dietary Supplement Health and Education Act of 1994, Pub. L.
No. 103-417, 108 Stat. 4325 (1994); see also William J. Skinner, R.Ph., J.D.,
Allowable Advertising Claims for Dietary Supplements, 5 J. PHARMACY & L.
309, 313 (1996). Medicinal herbs now constitute the most rapidly growing
2000]
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manufacturers to produce dietary supplements with a significantly
lower level of oversight by the FDA. The DSHEA departed from the
established regulatory scheme and took away FDA's authority to po-
lice a market now flourishing with unproven products that may present
not only efficacy issues, but safety concerns as well.
In the last few years dietary supplements received extensive media
exposure. In 1998, the world watched Mark McGwire batted his way
into the history books, breaking the Major League Baseball record for
most home runs in one season.2 ' As the season ended, the world also
took notice of the dietary supplements McGwire was taking, particu-
larly Androstenedione. 22 This so-called "supplement" is a derivative
of rigorously regulated, prescription-only anabolic steroids. 3 Like its
prescription drug counterpart, Androstenedione raises the level of
testosterone in the body and, arguably, helps build muscle. 24 Unlike its
counterpart, however, Androstenedione is not rigorously regulated and
can be purchased easily over the Internet.
25
This Comment traces the development of food and drug law leading
up to the DSHEA and the issues the FDA faces in attempting to regu-
late dietary supplements. Part I of this Comment discusses the history
of the Food Drug & Cosmetic Act (FDCA) as it relates to dietary sup-
plements. Part II highlights the evolution of the legal classification of
segment of the dietary supplement market in the U.S. See NIH RESEARCH
WORKSHOP, supra note 5, at 1.
20. See, e.g., Catherine Heusel, Self's Ultimate Guide to Herbal Medi-
cines, SELF, Nov. 1998, at 162. In 1997, the leading uses of herbal remedies
were: colds 59 percent, burns 45 percent, headaches 22 percent, allergies 21
percent, rashes 18 percent, insomnia 18 percent, PMS 17 percent, depression
7 percent, diarrhea 7 percent, menopause 4 percent. See also Jane E. Brody,
Taking a Gamble on Herbs as Medicine, N.Y. TIMES, Feb. 9, 1999, at D7
(citing Prevention Magazine).
21. See Frank Ahrens, Power Pill: How the Experts View Androstenedi-
one, WASH. POST, Oct. 20, 1998, § HM (Health), at 12.
22. See id.
23. See David Brown, McGwire's Tonic is a Steroid - of Uncertain Ef-
fect, WASH. POST, Sept. 28, 1998, at A3.
24. See Michael Colgan, Androstenedione and Tales of Testosterone,
(visited Oct. 20, 1998) <http://muscu lardevelopment.com/oct/andro I/html>.
25. A simple Internet search on Yahoo.com produced over 500 web sites
selling Androstenedione.
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dietary supplements and how the FDA enforces these standards. It
points out the struggle between the FDA and Congress to devise a
regulatory scheme to protect consumers, while also giving freedom to
supplement manufacturers. Part III of this Comment discusses how the
current regulatory scheme applies to supplements such as Androstene-
dione and St. John's Wort and highlights some of the scientific re-
search conducted on these products. In Part IV, this Comment argues
that the DSHEA is a departure from the FDA's intended regulatory
scheme. It suggests alternate ways the FDA can use DSHEA's provi-
sions to recapture some of the regulatory authority purposely removed
by the statute. Finally, this Comment recommends a more hands-on
role for the Federal Trade Commission (FTC) in monitoring supple-
ment labels and suggests possible cooperation between the FDA and
dietary supplement manufacturers to ensure consumer safety.
I. NEARLY A CENTURY OF FOOD AND DRUG LAWS
The FDA's initial authority over dietary supplements started with
efforts to protect consumers from bogus products marketed as having
health value. 26 Litigation and distrust between pharmaceutical compa-
nies and the FDA permeate the history of dietary supplement regula-
tion. The FDA and Congress sought to control dietary supplements
through a variety of enforcement and regulatory controls, including
classification methods, effectiveness provisions, and labeling require-
ments.27 On a case-by-case basis, the FDA very successfully con-
trolled the availability of products labeled as dietary supplements.
29
The FDA's efforts to create formal rules based on these victories did
not enjoy the same level of success. Attempts at regulation met strong
opposition from the dietary supplement industry. As a result, the
DSHEA has weakened federal control more than any other congres-
sional action surrounding food regulation.
2 9
26. For a thorough examination of the history of government regulation
of health claims for vitamins and minerals, see Peter Barton Hutt, Govern-
ment Regulation of Health Claims in Food Labeling and Advertising, 41
FOOD DRUG CosM. L.J. 3 (1986).
27. See infra Part II.
28. See infra Part II.A.
29. See William R. Pendergast, Dietary Supplements, in I
FUNDAMENTALS OF LAW AND REGULATION 257 (FDLI 1997).
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A. The Pure Food and Drugs Act of 1906
Congress enacted the Pure Food and Drugs Act of 190630 to help en-
sure the purity and safety of food and drugs and to prevent manufac-
turers from deceiving consumers. 31 It was passed at a time when in-
vestigative journalists, among them Upton Sinclair in The Jungle,
were disclosing the hidden side of the food industry. 32 Burgeoning
science also began providing increased opportunities to detect food
contamination. 33 Years of study and developments in technology of-
fered the means to chemically identify a variety of products and their
possible uses and effects. Although rather limited in scope, this leg-
islation was extraordinarily important for the safety of consumers.
Drugs marketed in interstate commierce were now subject to minimal
standards for quality, purity and strength.34 False claims about a drug's
therapeutic effect, however, were not a violation of the statute.
35
Although later amendments created a standard for misbranded
claims,36 the 1906 Act protected the public, to a degree, from unsafe
drugs even though it did not require pre-market screening. The need
for a drug screening regulation became apparent to Congress in 1938
when seventy-three people died after ingesting Elixir Sulfanilamide.37
30. Pub. L. No. 59-384, ch. 3915, 34 Stat. 768 (1906) (repealed 1938).
31. See 40 Cong. Rec. 9068-76 (1906).
32. See George M. Burditt, Esq., The History of Food Law, 50 FOOD &
DRUG L. J. 197 (1995).
33. See id.
34. See Edgar R. Cataxinos, Note, Regulation of Herbal Medications in
the United States: Germany Provides a Model for Reform, 1995 UTAH L.
REV. 561, 562-63 (1995).
35. See United States v. Johnson, 221 U.S. 488, 497-98 (1911) (holding
that an "effective against cancer" indication on drug label did not constitute
violation of 1906 Act).
36. See Cataxinos, supra note 34 (citing Joseph L. Fink & Larry M. Si-
monsmeier, Laws Governing Pharmacy, in REMINGTON'S PHARMACEUTICAL
SCIENCES 1890, 1907 (Alfonso R. Gennaro et al. eds., 17th ed. 1985)).
37. See David F. Cavers, The Food, Drug, and Cosmetic Act of 1938: Its
Legislative History and Its Substantive Provisions, 6 LAW & CONTEMP.
PROBS. 2, 20 (1939). The elixir contained the poisonous liquid diethylene
glycol, also known as antifreeze. See id. New drug provisions now require
thorough testing before a new drug can be marketed. See 21 U.S.C. § 355
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B. The Federal Food, Drug, and Cosmetic Act of 1938
To remedy the limitations of the Pure Food and Drugs Act and ex-
pand federal protection of consumers from unsafe, unproven, and
misleading products, Congress passed the Federal Food, Drug, and
Cosmetic Act of 1938 (FDCA).38 A product containing a vitamin, de-
pending on the way it was marketed and labeled, could be a food, a
drug, or both.39 No specific classification for vitamin/herbal products
existed. The FDCA included a labeling requirement and gave the FDA
power, under section 403(j), to regulate and declare misbranded die-
tary foods.40 The section stated that a food was misbranded
[i]f it purports to be or is represented for special dietary
uses, unless its label bears such information concerning
its vitamin, mineral, and other dietary properties as the
Secretary determines to be, and by regulations pre-
scribes as, necessary in order to fully inform purchasers
as to its value for such uses.4 '
Foods offered for "special" dietary uses, therefore, needed greater
attention and regulation than regular foods.42 This section and the
regulations to be implemented pursuant to it in the 1940s gave the
FDA the power to prescribe criteria for evaluating the nutritional
properties of a product and to control how that information reached
(1998).
38. Pub. L. No. 75-717, § 675, 52 Stat. 1040 (1938).
39. See Pendergast, supra note 29, at 257.
40. See21 U.S.C. § 403) (1998).
41. Id.
42. See Cavers, supra note 37, at 30. Some believed that products with a
vitamin/herbal content needed special attention. As one FDA official wrote
At that time [1939], the marketing of special dietary
products was confined largely to so-called "health-food
stores." Many. of the products then distributed were de-
Signed to meet the whims and fancies of food faddists
which had been cultured by the unscientific teachings of
nutritional quacks. There were, of course, a few bona-
fide foods for special dietary uses intended for diabetics
and others havingspecial dietary needs. These, however,
were few in number and were generally characterized by
a tastelessness or lack of palatability which discouraged
their purchase and use by others than those having a
genuine need for them.
Ralph F. Kneeland, Jr., Foods for Special Dietary Uses Under the Federal
Law, II FOOD DRUG COsM. L. J. 41, 41 (1956).
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consumers. 43 Although the FDA promulgated regulations pursuant to
section 403(j), the regulations were not as comprehensive as the
statutory language permitted. As a result, the question of how certain
products would be classified and regulated when they were labeled for
"special dietary uses" was left unanswered." The section 4030) regu-
lations focused primarily on the nutritional inadequacy of the Ameri-
can diet,4' not on how to regulate or control the safety and efficacy of
dietary supplements. Rather than define acceptable claims for these
products, the regulations established three classes of products,46 set
minimum daily requirements (MDR) for certain vitamins and miner-
als, and stated that the products which fell into these categories had to
list each MDR.47 Apart from the regulations, the FDA opted to employ
litigation-based authorities to regulate therapeutic or health-benefit
claims made on behalf of special dietary foods as drug claims. 48 This
policy decision led to FDA litigation throughout the 1940s and early
1950s concerning false claims in the labeling and advertising of vita-
43. See Pendergast, supra note 29, at 259.
44. See 6 Fed. Reg. 5921 (1941). The regulations' Findings of Fact
stated, "[T]he value of a food for special dietary use may depend on its suit-
ability for the treatment of a deficiency disease." Id. at 5921 n. 5.
45. See Michael F. Markel, Foods for Special Dietary Uses - An His-
torical Outline of Regulatory Aspects, 22 FOOD DRUG COSM. L.J. 110, 114
(1967).
46. See 6 Fed. Reg. 5921 (1941). The regulations defined "special die-
tary uses" as products that:
1) supply a particular dietary need "which exist[s] by rea-
son of a physical, physiological, pathological or other
condition," 2) supply a special dietary need by "which
exist[s] by reason of age" and 3) are intended to supple-
ment the diet with vitamins, minerals, or "other dietary
Id. property."
47. See 6 Fed. Reg. 5925 (1941). The agency later decided that the MDR
requirements did not go far enough to control vitamin-mineral products. See
MERRILL & HUTT, supra note 10, at 212.
48. See 6 Fed. Reg. 5921 (1941). The regulations stated: "No provision
of any regulation under section 4030) of the Act shall be construed as ex-
empting any food from any other provision of the Act or regulations thereun-
der, including sections 403(a) and (g) and, when applicable, the provisions of
Chapter V." Id.
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mins. 49 This series of cases, culminating with "The Nutrilite Consent
Decree,"5 established non-binding, industry-wide guidelines for le-
gally acceptable labeling of vitamin and mineral dietary
supplements.5 ' The guidelines provided that a vitamin-mineral product
label could not claim the product is "effective to prevent or adequately
treat or cure" any disease, but could promote the product "as a food
supplement to supplement or fortify the diet of any person" suffering
from a disease.5 2 The FDA enforced these guidelines through aggres-
sive and remarkably successful litigation.53
C. The Regulation of Dietary Supplements Before 1990
With this regulatory construct in place, the FDA waged a battle
between the 1940s and 1960s both in the courtroom and in the market-
place.54 In particular, herbs were considered a suspect class because
49. Many of these early cases dealt with food manufacturers falsely
claiming their products contained specific vitamins. See Lekas & Drivas,
Inc. v. Federal Trade Comm'n, 145 F.2d 976, 976 (2d Cir. 1944). For an ex-
amination of the history of government regulation of health claims for vita-
mins and minerals see Hutt, supra note 26, at 3 (1986).
50. United States v. Mytinger and Casselberry, Inc. FDA Not. of Jud. No.
3383 (S.D. Cal. 1951), reprinted in FEDERAL FOOD DRUG AND COSMETIC ACT
1951-1952, at 204 (FDLI 1953).
51. For a more complete discussion of the intricacies surrounding the
signing of the Nutrilite Consent Decree, see Ewing v. Mytinger & Cassel-
berry, Inc., 339 U.S. 594, 594 (1950); see also Lester L. Lev, The Nutrilite
Consent Decree, 7 FOOD DRUG COSM. L J. 56, 56 (1952).
52. Hutt, supra note 26, at 52. The Decree also found the label of the
vitamin-mineral product must clearly enumerate "all the purposes and condi-
tions for which the product is intended." Id.
53. See Pendergast, supra note 29, at 266.
54. The FDA and the AMA jointly sponsored two meetings of the Na-
tional Congress on Medical Quackery, which focused primarily on nutritional
quackery. See Mark A. Kassel, From a History of Near Misses: The Future
of Dietary Supplement Regulation, 49 FOOD & DRUG L.J. 237, 254 n.134
(1994) (citing FDA's CAMPAIGN AGAINST NUTRITIONAL QUACKERY;
PROGRESS REPORT (Oct. 1963)). The FDA brought over 100 actions against
vitamin-mineral products between 1961 and 1963. See id. Many of these
were won without litigation, that is, they were won either by default or a con-
sent decree. See id.
2000]
472 Journal of Contemporary Health Law and Policy [Vol. 16:463
they were long used by charlatans and quacks. 55 Herbs had a history of
medicinal and food uses which made them difficult to classify. 56 Sec-
tion 4030) could have addressed the dietary properties of herbs, but
did not. 57 Instead, the FDA pursued case-by-case enforcement of mis-
leading claims and other forms of "quackery,"' 8 yet it soon found that
this was not the most efficient use of resources.' 9
In 1962, in an effort to counter aspects of this inefficiency, the FDA
proposed regulations, which, if the dosage levels of the supplements
remained close to the U.S. Recommended Daily Allowance (RDA),
would have permitted the sale of single-nutrient dietary supplements
and limited the number of multi-vitamin and mineral products. 60 The
regulations would have also classified and processed "high potency"
type dietary supplements as drugs. 6' These proposals, however, met
great opposition from the public and burdened the rulemaking
process.
62
Since dietary supplements could, under the law, be considered a
food, a drug, or both, depending on how the products were marketed,
it was possible to control the market through drug regulations strictly
governing product labeling. The Drug Amendments of 1962 tightened
controls on products classified and sold as drugs.63 For the first time in
55. See Pendergast, supra note 29, at 262. Charlatans also promoted
them for inappropriate uses, inherently placing them in the category of
fraudulent products. See id.
56. See id. See also, e.g., William W. Goodrich, Challenging Quackery
with Truth, 16 FOOD DRUG COSM. L. J. 684 (1961).
57. See Pendergast, supra note 29, at 262.
58. One of the first statutes to deregulate drugs was passed in England in
1542. The "Quacks Charter" allowed registered physicians to administer in-
ternal medicines while folk healers and apothecaries were free to prescribe
topical medicines. See G. CLARK, A HISTORY OF THE ROYAL COLLEGE OF
PHYSICIANS OF LONDON 86 (1964).
59. See Kassel, supra note 54, at 254-55.
60. See 27 Fed. Reg. 5815, 5815 (1962).
61. See id.
62. See Kassel, supra note 54, at 255.
63. See Act of October 10, 1962, Pub. L. No. 87-781, 76 Stat. 780
(1962). See also 21 U.S.C. § 408 and accompanying regulations. A new
drug must undergo a series of tests and trials to prove that the drug is safe
and accomplishes what it claims. See 21 U.S.C. § 355.
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U.S. history, the FDA required manufacturers to demonstrate a "new
drug's" effectiveness before it was marketed. 64 This change required
new drug manufacturers to submit test-based information showing
"substantial evidence" the drug satisfied the claims made on the label
and could be used safely.6 Thus, the manufacturers bore a substantial
burden to show, through well-controlled studies, that the product was
effective for each of the claims made. 66 The FDA would not allow the
marketing of a product until this burden had been satisfied. The new
regulations gave the FDA control over what could be claimed by a
manufacturer as to how a product could be used.
Although the courts generally upheld the FDA's efforts to apply the
Act's drug standards to dietary supplement manufacturers, 67 such sup-
plements began to gain prominence in the marketplace. 68 Dietary sup-
plements and herbs had been used for many years in limited circles,
but in the 1970s they began to find a larger consumer base.69 In re-
sponse, the FDA increased its efforts to control the vitamin and sup-
plement market.70 For example, the FDA tried to make rules to classify
and regulate large doses of vitamins A and D as drugs simply on the
basis of potency, and to require labeling statements about the need for
and value of vitamin supplementation.7' The U.S. Court of Appeals for
the Second Circuit struck down the regulation on procedural
grounds.72 In anticipation of further agency activity, the vitamin in-
dustry mounted a, massive lobbying effort resulting in legislation
slightly limiting the FDA's ability to regulate dietary supplements.
The Proxmire Vitamin Mineral Amendment of 1976 expressly pro-
vided that the FDA:
64. See Act of October 10, 1962, Pub. L. No. 87-781, § 102, 76 Stat. 780
(1962).
65. See id.
66. See 21 U.S.C. § 355(b)(1) (1998); see also S. Rep. No. 87-1744, at
2891 (1962).
67. See infra Part II.A.
68. See Brody, supra note 20, at D7.
69. See Catherine Fahey, Herbal Medicine Moves Into the Mainstream,
UTNE READER, Mar.-Apr. 1991, at 42.
70. See Pendergast, supra note 29, at 257.
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(A) may not establish ... maximum limits on the po-
tency of any synthetic or natural vitamin or mineral ;
(B) may not classify any natural or synthetic vitamin
or mineral . . . as a drug solely because it exceeds a
level of potency which (the agency) determines is nu-
tritionally rational or useful...
(C) may not limit . . . the combination or number of
any synthetic or natural (i) vitamin, (ii) mineral, or (iii)
other ingredient of food. 3
These amendments were the first attempt at defining and regulating
vitamins and minerals marketed for special dietary uses. Although
significant for establishing a precedent, the 1976 amendments had lit-
tle impact on the FDA's aggressive regulation of dietary supplements.
D. The Nutritional Labeling and Education Act of 1990
The FDA received additional labeling authority over foods, includ-
ing dietary supplements, with the passage of the Nutrition Labeling
and Education Act (NLEA).74 The NLEA required food manufacturers
to include nutritional labeling on most food products "intended for
human consumption and offered for sale.""5 These labels required in-
formation concerning the number and size of servings in the product,
76
calorie and fat content," and any vitamin, mineral or nutrient "if the
Secretary determine[s] that such information will assist consumers in
maintaining healthy dietary practices. 78 The NLEA also provided
meaningful information about diet and health on food labels. This law
opened the door for more effective, yet lenient, regulation of dietary
supplement labeling. The key provision, codified at section
343(r)(5)(D) states:
[a] claim (in the label about any nutrient contained in
the product relating to a disease or health related con-
73. 21 U.S.C. § 350(1) (1998).
74. Act of November 8, 1990, Pub. L. No. 101-535, 104 Stat. 2353 (1990)
(codified at 21 U.S.C. §§ 343(q), 343(r) (1998)).
75. 21 U.S.C. § 343(q)(1) (1998).
76. See id. at § 343(q)(1)(A)(i).
77. See id. at § 343(q)(1)(C).
78. See id. at § 343 (q)(E). This statute touches a wide range of food la-
beling issues including nutritional content, nutritional descriptors and "health
claims." See Samia Rodriquez, Food Labeling, in I FUNDAMENTAL OF LAW
& REGULATION ch. 8 (FDLI 1997).
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dition) made with respect to a dietary supplement of
vitamins, minerals, herbs, or other similar nutritional
substances shall ... be subject to a procedure and stan-
dard, respecting the validity of such claim, established
by regulation of the Secretary.79
The NLEA required the FDA to promulgate procedural regulations
regarding how to establish such "health claims.,,80 The FDA deter-
mined the criteria for approving health claims would apply equally to
both traditional foods and dietary supplements.8 '
Not surprisingly, opponents mounted a legislative lobbying effort to
prevent the FDA from implementing regulations regarding health
claims appearing on the labels of dietary supplements. 82 Congress re-
acted to the lobbying efforts by passing the Dietary Supplement Act of
1992 (DSA),83 which stalled the regulation process.8 4 The DSA estab-
lished a one-year delay on the implementation of the NLEA and re-
quired the FDA to submit reports and studies on the issues surround-
79. 21 U.S.C. § 343(r)(5)(D) (1998). This provision has been described
as a "sweeping reversal of the agency's previous policy. Until the mid-
1980's, the FDA regarded all health claims as attributes ... subject to pre-
market approval." Fred R. Shank, The Nutritional Labeling and Education
Act of 1990, 47 FOOD & DRUG L.J. 247, 251 (1992).
80. See Act of November 8, 1990, Pub. L. No. 101-535, § 2(b), 104 Stat.
2353 (1990). See also Kassel, supra note 54, at 261. The specific claims
mentioned in the NLEA include: the link between folic acid and prevention
of neural tube defects; antioxidant vitamins as a means of preventing or cur-
ing cancer; the link between zinc and immune functions in the elderly; and
the omega-3 fatty acids' role in the possible prevention of heart disease. See
Pub. L. No. 101-535, § 3(b)(l)(A)(x), 104 Stat. 2361 (1990).
81. See 56 Fed. Reg. 60537, 50539 (1991).
82. See, e.g., Anthony J. lannarone, Scientific Basis for Health Claims
for Dietary Supplements, 47 FOOD & DRUG L.J. 665, 665 (1992) (The author,
the Associate Vice President of Hoffman-La Roche Inc., discusses the stan-
dards set forth in the NLEA and their opposition to the FDA's interpretation
of such standards.).
83. Dietary Supplement Act of 1992, Pub. L. No. 102-571, 106 Stat. 4491
(1992).
84. This statute indicates Congress wanted the FDA to reexamine its
stance on allowable health claims for dietary supplements. See Dietary Sup-
plement Act of 1992, Pub. L. No. 102-571, 106 Stat. 4491, 4500 (1992).
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ing dietary supplements." This action aimed to limit the FDA's abil-
ity to restrict regulations and implement limits on the dietary supple-
ment market.86
In the years between the Proxmire Amendments and the NLEA,
public health problems associated with the use of dietary supplements
became more apparent. In particular, the adverse health effects and
deaths associated with amino acids containing L-tryptophan came to
light in 1989. 8' The FDA issued a warning, which urged the public to
avoid supplements containing L-tryptophan, and detained foreign im-
ports. 88 The FDA then established a task force to examine the prob-
lems associated with daily supplements such as vitamins and minerals,
amino acids, herbs, and "other substances."8 9 The task force recom-
mended the following: (1) regulate supplements as drugs, because of
the medicinal claims made by the producers, or when they are used for
anything other than as food additives; and (2) regulate the supplements
as food additives unless claims of drug uses are made, thus moving
85. See Dietary Supplement Act of 1992, Pub. L. No. 102-571, § 202(a),
(b), 106 Stat. 4501 (1992). The Act prevented the FDA from issuing regula-
tions concerning dietary supplements until at least December 15, 1993.
These reports must include issues surrounding dietary supplements and the
national health, such as a report to Congress by the FDA on the agency's en-
forcement priorities and practices, a General Accounting Office (GAO) study
of the FDA's management activities, and an Office of Technology Assess-
ment safety and regulatory outcomes study. See id. § 204-206.
86. See Pendergast, supra note 29, at 272.
87. See Sean Harmon, Comment, Melatonin Mania: Can the FDA
Regulate Hormonal Dietary Supplements to Protect Consumer Interests in
Light of the Dietary Supplement Health Education Act of 1994?, 22 U.
DAYTON L. REV. 77, 82 (1996). See also Cathy Anne McGowan, Learning
the Hard Way: L-tryptophan, the FDA & the Regulation of Amino Acids, 3
CORNELL J.L. & PUB. POL'Y 383 (1994). L-tryptophan was one of the ingre-
dients in an amino acid supplement, which was found to be contaminated.
The contaminated L-tryptophan led to an outbreak of eosinophilia myalgia
syndrome (EMS), a disease of the systemic connective tissues characterized
by an increase of a special type of white blood cells, severe muscle pain, and
"cutaneous (skin) and neuromuscular manifestations." 58 Fed. Reg. 33,690,
33,696 (1993).
88. See 58 Fed. Reg. at 33,696.
89. 58 Fed. Reg. at 33,691.
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them into the drug category. 90 Because supplement manufacturers
made statements that resembled health claims, the task force recom-
mended that dietary supplements be regulated as drugs.91 The FDA's
task force signaled, yet again, an aggressive posture against dietary
supplements. In the face of near certain increased FDA activity, Con-
gress stepped in, disregarded these suggestions, and passed the
DSHEA, dramatically limiting the FDA's ability to regulate these
products.92
E. The Dietary Supplement Health and Education Act of 1994
It was apparent the FDA was not going to change its aggressive
stance on applying the NLEA to dietary supplements or the need to
aggressively police the marketplace for unsafe supplements. 93 In re-
sponse, Congress passed the DSHEA94 as an effort to restrict the
FDA's control on the dietary supplement market.95 The DSHEA cre-
ates a broad, comprehensive definition of "dietary supplement," 96 al-
lows retailers to sell third-party books and other educational materials
concerning dietary supplements, 97 and attempts to clarify permissible
90. See 58 Fed. Reg. at 33,697 (discussing the findings of the Dietary
Supplement Task Force Report).
91. See 58 Fed. Reg. at 33,694, 33,697.
92. See Harmon, supra note 87, at 83.
93. In the interim between the passage of the DSA and the DSHEA, the
FDA completed reports detailing the unsubstantiated claims of dietary sup-
plements. See Pendergast, supra note 29, at 272.
94. Pub. L. No. 103-417, 108 Stat. 4325 (1994).
95. The DSHEA was sponsored by Sen. Orrin Hatch (R-Utah), who
urged more lenient standards for dietary supplements. See 103 Cong. Rec.
16,611 (daily ed. Oct. 24, 1990). Many dietary supplement manufacturers
are located in Utah. See Pendergast, supra note 29, at 272.
96. See Pub. L. No. 103-417, § 3, 108 Stat. 4325 (1994); see also U.S.
Food and Drug Admin. Ctr. for Food Safety and Applied Nutrition, Dec. 1,
1995, (visited Oct. 20, 1998) <http://vm.cfsan.fda.gov/-dms/dietsupp.html>.
Congress expanded the meaning of the term "dietary supplements" beyond
essential nutrients to include such substances as ginseng, garlic, fish oils,
psyllium, enzymes, glandulars, and mixtures of these. See id.
97. See Pub. L. No. 103-417, § 5(a), 108 Stat. 4325 (1994); see also U.S.
Food and Drug Admin. Ctr. for Food Safety and Applied Nutrition (last
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claims that may appear on the labels of dietary supplements. 98 Manu-
facturers may not claim their products diagnose, prevent, mitigate,
treat or cure a specific disease, unless approved under the new drug
provisions of the FDCA. 99 Manufacturers may, however, make claims
with respect to the supplement's effects on the body's well-being,
"structure or function," and even a person's mood. 00 Unlike health
claims, FDA approval is not required for these claims before the prod-
uct enters the market.' 0' If a dietary supplement manufacturer wants
to make therapeutic or disease related claims, the product must be
classified as a drug'02 and undergo the necessary approval process. In
light of the ability to make "structure or function" claims, there is a
fine line between what is and is not a permissible claim.'
0 3
DSHEA also requires the formation of various offices and commis-
sions to recommend labeling requirements, to study the information
circulating to the consumers, and to analyze the eventual health effects
modified Dec. 1, 1995) <http://vm.cfsan.fda.gov/-dms/dietsupp.html>.
98. See Pub. L. No. 103-417, § 6(c), 108 Stat. 4325 (1994).
99. See id.
100. See id. at § 6(a), 108 Stat. at 4325. Products may state claims such
as "helps relieve anxiety," and "helps you feel good mentally." See Maria
Toscano, Risks and Rewards: What you need to know about the 22 best-
sellers, SELF, Nov. 1998, at 163.
101. To use these claims, however, manufacturers must have substantial
proof that the statements are truthful, not misleading, and the product label
must bear the statement: "This statement has not been evaluated by the Food
and Drug Administration. This product is not intended to diagnose, treat,
cure, or prevent any disease." Pub. L. No. 103-417, § 6(c), 108 Stat. 4325
(1994). See also Food and Drug Admin. Ctr. for Food Safety and Applied
Nutrition, (last modified Dec. 1, 1995) <http://vm.cfsan.fda.gov/-dms/
dietsupp.html>.
102. The DSHEA defines "drug" as: "(B) articles intended for use in the
diagnosis, cure, mitigation, treatment or prevention of disease ... ; and (C) ar-
ticles (other than food) intended to affect the structure or any function of the
body of man. .. ." 21 U.S.C. § 321(g) (1998).
103. See Fred H. Degnan, Impact of the Agency's Sept. 1997 Dietary
Supplement Regulations and April 29, 1998 Notice on "Structure or Func-
tion" Claims on Harmonizing the Regulation of Foods and Dietary Supple-
ments (on file with author).
From Herbal Prozac to Mark McGwire's Tonic
of the supplements. 0 4 DSHEA created a seven-member commission-
on Dietary Supplement Labels'0 5 with the responsibility of conducting
studies on, and providing recommendations for, the regulation of label
claims and statements for dietary supplements and the use of literature
in connection with the sale of dietary supplements.10 6 Another function
was to make recommendations on procedures for the evaluation of
such claims. Its report was released in 1997.07
The DSHEA also created the Office of Dietary Supplements within
the National Institute of Health. 0 8 The office has two purposes: (1)
explore the potential role of dietary supplements in the U.S. and (2)
promote scientific study of dietary supplements in maintaining health
and preventing chronic disease and other health-related conditions.
0 9
II. THE FDA'S "WEAPONS" AGAINST UNSAFE PRODUCTS
A. Regulation and Litigation Prior to the DSHEA
Prior to the NLEA and the DSHEA, the FDA used its litigation and
rulemaking strategies to protect the public from unsafe and question-
104. See Pub. L. No. 103-417, § 12(a), 108 Stat. 4325 (1994). See also
Food and Drug Admin. Ctr. for Food Safety and Applied Nutrition, (last
modified Dec. 1, 1995) <http://vm.cfsan.fda.gov/-dms/dietsupp.html>.
1105. See Pub. L. No. 103-417, 12(b), 108 Stat. 4333 (1994). The mem-
bers of the Commission shall consist of individuals with expertise and exper-
ience in dietary supplements and in the manufacture, regulation, distribution,
and use of such supplements. See id. At least three of the members of the
Commission shall be qualified by scientific training and experience to evalu-
ate the benefits to health of the use of dietary supplements. See id. One of
the three members shall have experience in pharmacognosy, medical botany,
traditional herbal medicine, or other related sciences. See id. Members and
the staff of the Commission shall be without bias on the issue of dietary sup-
plements. See id.
106. See id. at § 12(c), 108 Stat. at 4333.
107. See COMM'N ON DIETARY SUPPLEMENT LABELS, COMM'N ON
DIETARY SUPPLEMENT LABELS REACT TO THE PRESIDENT, CONGRESS, AND
THE SECRETARY OF THE DEP'T OF HEALTH AND HUMAN SERVICES (Nov.
1997). Also available at <http://web.health.gov/dietsupp>.
108. See Pub. L. No. 103-417, § 13(a), 108 Stat. 4334 (1994).
109. See id.
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able products. One of the FDCA's many purposes is to protect con-
sumers from adulterated and unsafe products." 0 In passing the FDCA
in 1938, Congress anticipated that vitamin/mineral products would be
regulated closely."' Section 4030) of the FDCA," 2 which gave the
FDA the power to define and regulate misbranded food, provided the
FDA with the opportunity to comprehensively oversee dietary sup-
plements through regulations prescribing the contours of their use.
1 13
The FDA, however, opted to follow a less comprehensive course of
rulemaking by limiting the scope of section 4030) regulations to de-
scribe the nutritional qualities of a food. 1 4 The FDA controlled die-
tary supplement claims through aggressive and creative litigation, re-
lying on its authority over food and drug adulteration and misbrand-
ing. 5 Although effective in the short term, such a strategy proved to
be resource-intensive, hallmarked by individual victories, but resulting
in a failure to effect coniprehensive control over the supplement in-
dustry."
l6
Another option available to the FDA was to regulate dietary sup-
plements under statutory rubric applicable to foods and drugs. The
FDCA contains an array of product classifications including "foods,"
"drugs," "new drugs," and "cosmetics." '" 7 Each classification includes
110. See MERRILL & HUTT, supra note 10, at 3-4.
111. See Pendergast, supra note 29, at 259.
112. Pub. L. No. 75-757 § 403(j), 52 Stat. 1048 (1994) (codified at 21
U.S.C. § 3430)). There is very little legislative history surrounding § 4030),
it is acknowledged, however, that the section was intended to cover products
intended for "special nutritional requirements." S. Rep. No. 493, at 12
(1934). The Senate also recognized that the science of nutrition is rapidly
changing and there is a serious need for regulation authority. See id.
113. See Pendergast, supra note 29, at 259.
114. Those in favor of regulating vitamins and herbs as foods argued that
regardless of form, they were foods. See Markel, supra note 45, at 114. Pro-
ponents of regulating them as drugs argued that since they were packaged
and marketed as drugs, they were drugs. See id
115. See Cavers, supra note 37, at 30.
116. See id.
117. The FDCA classifies a product as a food, drug, or cosmetic. See 21
U.S.C. § 321 (1994). Dietary supplements are classified as foods. See 21
U.S.C. § 321(ff). One of the categories within the food classification is food
used for dietary purposes. See id.
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different statutory standards for product marketing. Moreover, the
classifications are not mutually exclusive. For example, dependent
upon how a product is used or labeled for regulatory purposes, it may
be a "food," a "drug," and a "new drug" simultaneously. 18 Some of
the earliest cases under this policy struggled to determine whether
substances such as processed foods 19 and wine' 20 should be consid-
ered foods. In addition, the courts attempted to determine whether
water with a "therapeutic effect"' 2' should be classified as a "food," a
"drug," or both.
22
Vitamin and mineral products proved to be particularly susceptible
to different classifications and regulatory standards under the FDCA.
For instance, such products could be regulated as "foods," "drugs," or
both, depending on their actual use and their labeling. 23 In U.S. v.
118. The FDCA defines "food" as "articles used for food or drink" and
components of such articles. See 21 U.S.C. § 321(0(1994). A "drug" is a
product that is used in the "diagnosis, cure, mitigation, treatment or preven-
tion of disease ... [or] to effect the structure or any function of the body." 21
U.S.C. § 321(g)(1994). See also Fred H. Degnan, The Food and Drug Con-
tinuum: Safety and Labeling Considerations Regarding Food and Disease
Prevention, 8 (on file with author).
119. See United States v. Ninety-Five Barrels, 265 U.S. 438 (1924)
(finding that vinegar, produced from dried apples by dehydration process
employing chemicals, was food); see also Union Dairy Co. v. United States,
250 F. 231 (7th Cir. 1918) (holding that milk was a food even though it was
shipped for treatment and purification).
120. See United States v. Sweet Valley Wine Co., 208 F. 85 (D. Ohio,
1913).,
121. See Bradley v. United States, 264 F. 79 (5th Cir. 1920).
122. See id. (finding that it was not a drug). Other examples of the FDA's
struggle to classify foods include: United States v. Six Dozen Bottles, 55 F.
Supp. 458 (D.Wis. 1944) (which concerned fennel); United States v. Five
Cases, 62 F. Supp. 736 (S.D.N.Y. 1945), rev'd on other grounds, 156 F.2d
493 (2d Cir. 1946); Research Lab., Inc.. v. United States, 167 F.2d 410 (9th
Cir. 1948), cert. denied, 335 U.S. 843 (1948) (concerning ginseng and sage).
123. The FDA attempted to set upper limits for vitamin and mineral in-
gredients, but these regulations were lost to challenges. See National Nutri-
tional Food Ass'n v. FDA, 491 F.2d 1141 (2d Cir. 1974); see also National
Nutritional Food Ass'n v. FDA, 504 F.2d 761 (2d Cir. 1965). The Proxmire
amendments ensured that products could not be defined as drugs based on
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Vitasafe,124 vitamin and mineral supplements were found to be both
"foods" and "drugs" within the meaning of the FDCA, and regulated
accordingly. 125 A single item may be classified not only as a "food"
because it has value as a dietary supplement, but also as a "drug" if it
claims to affect the body's structure and function, particularly with re-
gard to curing or preventing disease.1
26
Further, a product's intended use can be determined from the label
or its accompanying material. 27 If it appears that a "food" product is
used for medical purposes, then that product would be brought within
the definition of a "drug" and therefore mislabeled. 28 In addition, a
food product can also be considered a "new drug" and be subject to
pre-market approval. 29 Regulation as a "drug" and "new drug" im-
poses burdensome regulatory standards on a manufacturer to establish
the safety of drugs for their recommended uses.' 30 A dietary supple-
ment product can easily fall within the "drug" definition, provided it is
labeled or promoted to have some benefit relating to the cure, treat-
ment, prevention or mitigation of disease.' 31 A vitamin supplement
bearing an unsubstantiated claim can be misbranded as a "food" or a
"drug" as well as a "new drug," thus requiring extensive pre-market
their vitamin and mineral content. These amendments also prohibited the
FDA from putting limits on the amounts of vitamins and minerals in products
except for safety concerns. See Health Research and Health Services
Amendments of 1976, Pub. L. No. 94-278, 90 Stat. 401, 410 (1976); H.R.
Conf. Rep. No. 1005 (1976). Congress did, however, give the FDA the
authority to pursue those products with false or misleading advertising after
first notifying the FTC. The FTC has the opportunity to take action first.
See Pub. L. No. 94-278, 90 Stat. 401, 412 (codified at 21 U.S.C. § 378)
(1998); see also National Nutritional Food Ass'n. v. Kennedy, 572 F.2d 377
(2d Cir. 1978).
124. 345 F.2d 864 (3d Cir. 1965).
125. See Vitasafe, 345 F.2d at 864.
126. See United States v. Vitasafe, 226 F. Supp. 266 (D. N.J. 1964)
127. See United States v. Article ... Consisting of 216 Cartoned Bottles,
More or Less, 409 F.2d 734 (2d Cir. 1969).
128. See id.
129. See 21 U.S.C. § 355 (1998) (describing the new drug approval proc-
ess).
130. See 21 U.S.C. § 360(e) (1998).
131. See 21 U.S.C. § 321(g) (1998).
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safety testing before being able to be lawfully marketed.
It was to the FDA's advantage to try to classify those vitamin sup-
plements it viewed to be problematic as drugs for regulatory purposes.
To this end, the FDA successfully interpreted the definition of "label-
ing" in the FDCA to encompass a variety of practices employed by
manufacturers to promote their products. 32 By broadly construing la-
beling to encompass pamphlets, articles and even radio broadcasts, the
FDA was able to successfully establish supplement manufacturers'
"intent" to market drug-like therapeutic products. 133 By applying this
statute broadly, the FDA, through enforcement via litigation, ensured
the removal of unsafe or bogus vitamin and mineral products from the
marketplace with relative promptness.
34
Supplement manufacturers became more circumspect in making
therapeutic claims in the late 1970s and 1980s and therefore the FDA
attempted to classify certain dietary supplements as "food
additives.' 35 This statutory standard required pre-market demonstra-
tion of product safety. 136 Although proving that a supplement qualified
as a food additive was difficult, the agency succeeded in its efforts and
forced manufacturers to use only "safe" ingredients.
137
132. See Pendergast, supra note 29, at 263-64.
133. See United States v. Storage Spaces, 777 F.2d 1363 (9th Cir. 1985)
(intent can be determined from promotional materials or any other relevant
source of information). This broad interpretation of labeling helped to invoke
drug misbranding provisions and drug provisions. See also United States v.
Allen Drug Corp., 357 F.2d 713 (10th Cir. 1966); United States Article of
Drug, 263 F. Supp. 212 (D. Neb. 1967); United States v. 363 Cases, More or
less, Mountain Valley Mineral Water, 143 F. Supp. 219 (W.D. Ark. 1956);
United States v. 8 Cartons, 97 F. Supp. 313 (W.D.N.Y. 1951). This broad
interpretation of labeling helped to invoke drug misbranding provisions and
drug provisions. See id.
134. The DSHEA drastically changed this requirement, which now en-
courages information on supplements, so long as it is not brand particular, to
be available in the same area as the product. See infra note 146.
135. 21 U.S.C. §§ 321(s), 348 (1994).
136. See 21 U.S.C. § 360(e) (1994).
137. See United States v. Two Plastic Drugs ... Viponte Ltd. Black Cur-
rent Oil, 984 F.2d 814 (7th Cir. 1993); United States v. Article of Food, 792
F. Supp. 139 (D. Mass. 1992).
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B. "Weapons" under the NLEA
Passage of the NLEA gave the FDA a new weapon to regulate
claims made on behalf of dietary supplements. The NLEA gives the
FDA the authority to allow health claims138 to be placed on a supple-
ment only if the FDA "determines, based on the totality of publicly
available scientific evidence . . . that there is significant scientific
agreement, among experts qualified by scientific training and experi-
ence to evaluate such claims, that the claim is supported by such evi-
dence.' 39
The FDA has been very conservative with respect to the evaluation
of health claims. In the early 1990s, various studies showed that if an
expectant mother took proper amounts of folic acid, it could prevent a
variety of serious birth defects.140 The FDA did not approve the claim
until a year after the Public Health Service recommended that all
pregnant women consume adequate amounts of folic acid.14' This de-
lay prevented manufacturers from using the claim on labels and in ad-
vertisements. 42 The FDA made it clear that they would not jeopardize
public safety in the interests of expediency.143 Further, interpreting the
NLEA's application to supplements so conservatively gave the FDA
additional control over the benefits manufacturers could attribute to
138. See Nutrition Labeling and Education Act, Pub. L. No. 101-535 §
3(b)(1)(A)(vi) (1990). The NLEA allows claims regarding calcium and os-
teoporosis, dietary fiber and cancer, lipids and cardiovascular disease, lipids
and cancer, sodium and hypertension, and dietary fiber and cardiovascular
disease. See id.
139. 21 U.S.C. § 343(r)(3)(B)(i) (1998). Many researchers agree that
there are some supplements that work, and that manufacturers must carefully
test the products so that what is written on the label matches what is inside
the bottle. See Susan Okie, Information Gap on Herbal Products: All Parties
Agree More Research is Needed, but Who's Going to Foot the Bill?, WASH.
POST, Sept. 29, 1998, § HM (Health), at 7.
140. See S. Rep. No. 410, at 7 (1994).
141. See id. at 16.
142. See Harmon, supra note 87, at 84.
143. In the Senate report, the FDA commissioner, Dr. David Kessler, ex-
pressed the importance of "strik[ing] the right balance between ensuring the
safety and proper labeling of all these products while at the same time pre-
serving consumers' freedom of choice." S. Rep. No. 410, at 17 (1994).
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their products.
C. The DSHEA: Limiting FDA's Regulatory Weapons
Against the backdrop of. President Clinton's health care reform in
1993-94, Congress saw dietary supplements as an inexpensive way to
promote public health.1 44 Congress passed the DSHEA in an effort to
reconfigure how the FDA regulated dietary supplements. 45 The
DSHEA has three main concerns: research, labeling, and standard of
proof for safety. The DSHEA now allows certain types of statements
to be made without FDA approval. A statement can be made if it:
[C]laims a benefit related to a classical nutrient defi-
ciency disease and discloses the prevalence of such dis-
ease in the United States, describes the role of a nutri-
ent or dietary ingredient intended to affect the structure
or function in humans, characterizes the documented
mechanism by which a nutrient or dietary ingredient
acts to maintain such structure or function, describes
general well-being from consumption of a nutrient or
dietary ingredient.
These statements are not subject to pre-market review and approval
by the FDA.147 Moreover, difficulties and problems arise in distin-
guishing between permissible and impermissible claims. 48 For exam-
144. See Harmon, supra note 87, at 84.
145. See Pub. L. No. 103-417, 108 Stat. 4325 (1994). The Act is based on
the consumers' desire to learn about and take control of their own health and
diet to reduce the potential for disease. See Anthony L. Young & I. Scott
Bass, The Dietary Supplement Health and Education Act, 50 FOOD & DRUG
L. J. 285 (1995). "The purpose of creating this new framework was to strike
the right balance between providing consumers access to both products and
truthful information about the products while retaining authority for FDA to
take action against products that present safety problems or are improperly
labeled." Henney, supra note 9, at 15.
.146. 21 U.S.C. § 343(r)(6)(A).
147. See 21 U.S.C. § 342(f) (1998). The FDA needs to only review the
product if it contains a new dietary ingredient. See 21 U.S.C. § 413(a)(2).
148. The FDA has found instances where products with ingredients that
simulate illicit street drugs are being sold over the Internet to adolescents.
The statute's broad language which "must not allow the inclusion of ingredi-
ents never intended to fit within the universe of dietary supplements" has
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pie, the "structure or function" claim that a supplement "supports the
body's antiviral capabilities," would be questioned by the FDA as a
veiled drug claim. 149 On the other hand, a "supports the immune sys-
tem" claim would be viewed by the FDA as permissible. 150 In the first
statement, there is a suggested relationship between the product and a
health-related occurrence, which according to the statute, constitutes
an implied disease claim. Viruses are connected to human health while
the generality of boosting the immune system does not create such a
connection. In support of these distinctions, the FDA proposed rede-
fining "disease" as:
[a]ny deviation from, impairment of, or interruption of
the normal structure or function of any part, organ. or
system (or combination thereof) of the body that is
created problems for the FDA. See Henney, supra note 9, at 17.
149. See Fred Degnan, Making Sense Out of the Food/Dietary Supplement
Regulatory Dichotomies Created by the Dietary Supplement Health Educa-
tion Act, 11 [hereinafter Regulatory Dichotomies](on file with author).
150. See id. Other examples of impermissible claims are "reduces the
pain and stiffness associated with arthritis," "antibiotic," "antiseptic," "anti-
depressant," "lowers cholesterol," and "Herbal Prozac." Id. Claims such as
the following would be permissible: "[Hlelps promote urinary tract health,"
"promotes relaxation,". "an energizer," "reduces stress and frustration," and
"improves absentmindedness." Id. Supplement marketers petitioned the FDA
to approve four additional claims for supplements. See Pearson v. Shalala,
164 F.3d 650 (D.C. Cir. 1999). The four proposed claims were: "consump-
tion of antioxidant vitamins may reduce the risk of certain kinds of cancers,"
"consumption of fiber may reduce the risk of colorectal cancer," "consump-
tion of omega-3 fatty acids may reduce the risk of coronary heart disease,"
and" .8mg of folic acid in a dietary supplement is more effective in reducing
the risk of neural tube defects than a lower amount in foods in common
form." Id. at 652. The FDA refused to authorize the claims, arguing that
there was no "significant scientific agreement" concerning the claims. See
id. The court held that the decision not to authorize the claims violated the
First Amendment because the FDA did not consider evidence which could
make the claim non-misleading by adding qualifying language. See id. at
653. In response, the FDA has called for a public meeting to discuss imple-
mentation of the Pearson decision. See Public Meeting Concerning Imple-
mentation of Pearson Court Decision and Whether Claims of Effects on Ex-
isting Diseases May be Made as Health Claims, 65 Fed. Reg. 14219 (2000).
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manifested by a characteristic set of one or more signs
or symptoms, . . . includ[ing] laboratory or clinical
measurements that are characteristics of a disease.'
5'
Under this definition, an ailment can be described within certain pa-
rameters. If a dietary supplement claims to treat symptoms within
these parameters, it will be regulated by the FDA as a disease claim.
This proposed definition is designed to give the FDA enough flexibil-
ity to clarify and prohibit "structure or function" claims that imply
more than they can deliver.1
52
Not surprisingly, supplement manufacturers have strongly objected
to the FDA's proposed definition, alleging it exceeds the agency's
authority under the DSHEA and inappropriately restricts the dietary
supplement manufacturers.5 As a result of this opposition, the FDA's
Final Rule omits the proposed definition and retains the definition
used in the NLEA.154 The FDA concluded that the existing definition
covers conditions medically understood to be diseases. As such, the
FDA felt it unnecessary to adopt the proposed definition.' Rather
than tighten the controls on manufacturers, the Final Rule gives many
151. Proposed Rule, Regulations on Statements Made for Dietary Supple-
ments Concerning the Effect of the Product on the Structure or Function of the
Body, 63 Fed. Reg. 23625 (1998) (proposed to be codified at 21 C.F.R. pt.
101).
152. See Degnan, Regulatory Dichotomies, supra note 149, at 10. "The
American Medical Association supports the FDA's definition and would like
to expand it to include states of health leading to deviation, impairment, or
interruption.. ." Mike Mitka, FDA Never Promised an Herb Garden - But
Sellers and Buyers Eager to See One Grow, 280 JAMA 1554, 1555 (1998).
153. The FDA received over 230,000 submissions in response to the pro-
posed rule. See Regulations on Statements Made for Dietary Supplements
Concerning the Effect of the Product on the Structure or Function of the
Body, 65 Fed. Reg. 1000 (2000).
154. See id.
155. See 65 Fed. Reg. at 1010. The FDA now defines disease as "damage
to an organ, part, structure, or system of the body such that it does not func-
tion properly (e.g., cardiovascular disease), or a state of health leading to
such dysfunctioning (e.g., hypertension); except that diseases resulting from
essential nutrient deficiencies (e.g., scurvy, pellagra) are not included in this
definition." 65 Fed. Reg. at 1050 (to be codified at 21 C.F.R. § 101.93)
(1998).
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examples of conditions that are not diseases and therefore are allow-
able claims.
156
In addition, the DSHEA changed the standard of proof required be-
fore the FDA can remove a product from store shelves. 57 Manufactur-
ers are responsible for providing information to support their claims
and need not prove safety or effectiveness." 8 Instead, under the
DSHEA, the FDA bears the burden of proving the products are
unsafe. 159 Prior to the DSHEA, the FDA needed only to prove the
product contained a "poisonous or deleterious" substance that "may
render [it] injurious to health,' 160 or that the product contained an un-
approved food additive. Now the FDA must prove an ingredient "pre-
sents a significant or unreasonable risk of illness or injury under...
ordinary conditions of use," 16 1 a much more difficult standard.
162
Moreover, supplements are expressly removed from the definition of
"food additive" and can no longer be regulated as such. These new
standards turn attention away from the product itself and towards the
"intended use" of the product. While a supplement in itself may not
pose an unacceptable health risk, the risk could be very high if used
for a specific purpose. For example, a supplement recommended for
athletic performance may cause cardiovascular problems, but if the
product is not promoted for athletic use, the supplement would not be
156. See 65 Fed. Reg. 1000 (2000).
157. See Pub. L. No. 103-417, 108 Stat. 4325, 4328 (codified at 21 U.S.C.
§ 342).
158. See Rebecca Porter, Supplements Supply Dietary Danger as FDA
Looks On, TRIAL: J. OF THE Ass'N OF TRIAL LAW. OF AM., Oct. 1998, at 12.
159. See id.; see also, Usha Lee McFarling, Herbal Medicines Surge, an
Effort Opens to Promote Safety, PHILA. INQUIRER, Sept. 24, 1998, at A24.
160. 21 U.S.C. § 342(a)(1) (1998). The Supreme Court has not required a
finding that the product affected health and has found it sufficient that it
"may possibly injure the health" of humans. See U.S. v. Lexington Mill &
Elevator Co., 232 U.S. 399, 411 (1914); see also Flemming v. Florida Citrus
Exch., 358 U.S. 153 (1958).
161. 21 U.S.C. § 342(f)(1)(a) (1998).
162. According to the FDA Commissioner, DSHEA provides broad access
to dietary supplements while at the same time provides FDA with the frame-
work to remove products "that pose a 'significant or unreasonable' risk to
consumers or that are otherwise adulterated." Henney, supra note 9, at 5.
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considered adulterated. 63 This, in turn, places the burden on the FDA,
to substantiate concerns regarding both the ingredients and the claims
made by the product manufacturers. 64 Accordingly, attention is not
focused on the actual toxicity of the product itself, but the toxicity of
the product when used under ordinary conditions. Thus, even though a
supplement can be abused, leading to serious health risks, it may nev-
ertheless be allowed to remain in the marketplace. Simply put, under
the DSHEA a product does not raise actionable safety hazard concerns
if it can be shown that the supplement does not present a significant or
unreasonable risk of illness or injury under either the conditions of use
recommended in its labeling or, if no conditions of use are recom-
mended, under its "ordinary" conditions of use. This standard does
not provide anything comparable to the assurance of safety that nor-
mally accompanies lawfully marketed food additives and drugs.
III. WHERE Do ANDROSTENEDIONE AND ST. JOHN'S WORT
FIT INTO THE REGULATORY SCHEME?
Through the Food and Drug Act of 1938 and subsequent statutes,
the FDA possesses broad power to regulate substances consumed by
the public. The DSHEA creates an exception to this authority and
permits pharmacologically active substances like Androstenedione 165
and St. John's Wort 66 to be regulated as dietary supplements. These
products currently are not subject to the FDCA's demanding standards
for assuring the safety and efficacy of food additives and drugs. They
163. See Pendergast, supra note 29, at 278.
164. See id.
165. Androstenedione is a steroid hormone taken as an anabolic steroid.
However, unlike steroids, it is perfectly legal. See Brown, supra note 23, at
A3; see also Going for the Gold: Hard Work, Dedication - and Drugs,
NEWSWEEK, Feb. 15, 1999, at 51.
166. St. John's Wort is one of the most popular herbal supplements. It is
reported to relieve anxiety and mild depression. See Jane E. Brody, In the
Garden of Herbal Remedies, Weeding Out the Bad Choices, N.Y. TIMES,
Feb. 9, 1999, at D7; Catherine Heusel, What's Really in the Bottle: All St.
John's Wort is Not Alike, SELF, November 1998, at 166; Toscano, supra note
100, at 165; VARRO E. TYLER, HERBS OF CHOICE: THE THERAPEUTIC USE OF
PHYTOMEDICINALS (1999); Phytochemical and Ethnobotanical Databases
(visited Feb. 13, 1999) <http://www.ars-grin.gov/duke>.
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must be labeled, however, as "dietary supplements" 167 and must not
expressly indicate their use in the diagnosis, cure, mitigation, treat-
ment or prevention of disease.
168
Studies show Androstenedione and St. John's Wort act like drugs
when consumed and may produce adverse effects. 69 St. John's Wort
may cause nausea, stomach aches, fatigue, skin reactions and devel-
opmental problems in children whose mothers take the herb during
pregnancy. 70 It also weakens the effect of prescription medications
such as those taken for heart disease, cancer, and HIV. 17' If these
products were regulated as drugs, the FDCA would require explicit
proof that the products could be safely used for their intended pur-
poses. When labeled as dietary supplements, however, no such re-
167. 21 U.S.C. § 321(ff) defines a dietary supplement as a product that
contains "a vitamin; mineral; herb or other botanical; an amino acid; a die-
tary substance for use by man to supplement the diet ... a concentrate, me-
tabolite, constituent, extract, or combination of any ingredient described
[above]." The statute further states that dietary supplements are "to be a food
within the meaning of this Act." 21 U.S.C. § 321(ff)(3) (1998).
168. See 21 U.S.C. § 342(r).
169. See Okie, supra note 139, at 7; Porter, supra note 158, at 12; Real-
life Herbal Horror Stories, GLAMOUR, Feb. 1999, at 215-16; First US.
Clinical Trial of St. John's Wort, INSIDE MS, Summer 1998, at 30. See also
J. Parasrampuria, et al., Quality Control of Dehydroepiandrosterone Dietary
Supplement Products, 280 JAMA 1565, 1565 (1998); Lynn R. Grush et al.,
St. John's Wort During Pregnancy, 280 JAMA 1566, 1566 (1998); Fact
sheets on Alternative Medicine (visited Mar. 20, 1999) <http://cpmcnet. co-
lumbia.edu/dept/rosenthal/factsheets.html>; Edmund R. Burke, Androstene-
dione Caution, MotherNature.com Health Journal Newsletter (visited Aug. 2,
1999) <http://www.mothernature.com/news/1999_0609/ms.stm>; D. King, R.
Sharp, M. Vukovich et al., Effect of Oral Androstenedion on Serum Testos-
terone and Adaptations to Resistance Training in Young Men, A Randomized
Trial, 281 JAMA 2020 (1999); Consumer Guide to St. John's Wort, (visited
Aug. 2, 1999) <http://www.mothemature.com/cg/stjohnswortcg.stm>.
170. See Grush et al., supra note 169 at 1566 (1998); Consumer Guide to
St. John's Wort, (visited Aug. 2, 1999) <http://www.mothernature.com/
cg/stjohnswortcg.stm>.
171. See FDA Public Health Advisory: Risk of Drug Interactions with St.
John's Wort and Other Drugs (last modified Feb. 10, 2000) <http://www.
fda.gov/cder/drug/advisory/stjwort.htm>.
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quirements apply, even though consumers may use them for drug-like
purposes.
According to one group, Androstenedione should not be classified
as a dietary supplement because it is not part of a normal diet.' An-
drostenedione is a steroid hormone that is one metabolic step away
from testosterone. 173 Testosterone produces increased body hair, acne
and muscle growth. 174 It also boosts aggressiveness and stimulates
formation of red blood cells, giving the blood a higher "oxygen-
carrying capacity. 1 75 This physiological effect is usually referred to as
"anabolic" because it helps the body to build proteins, of which mus-
cles are the largest source in the body.
176
St. John's Wort has been called the all natural anti-depressant or
"herbal Prozac."'177 In Germany, St. John's Wort is prescribed more
than any other prescription anti-depressant. 7 8 Much like anti-
depressant drugs, St. John's Wort has multiple effects on the brain's
neurotransmitters.179 Since the manufacturers cannot make actual
medical claims, they purport that it can "help you feel good
mentally"'80 and "help fight the blues."'
8'1
A problem with marketing these products as "supplements" is many
172. See Endocrine Society Alert: "Andro" Use by Athletes (visited Oct.
5, 1998) <http://www.endo-society.org/newsg/press/andro.htm> [herinafter
Endocrine Society Alert]. See also Frank Ahrens, How the Experts View An-
drostenedione, WASH. POST, Oct. 20, 1998, § HM (Health), at 13.
173. See Brown, supra note 23, at A3.
174. See Endocrine Society Alert, supra note 172.
175. See Brown, supra note 23, at A3.
176. See id.
177. See J. Madeleine Nash, Nature's Prozac?, TIME, Sept. 22, 1997, at
80. Prozac is one of the most commonly prescribed anti-depressant drugs in
the United States. See Michael T. Murray, Battling the Blues with St. John's
Wort, BETTER NUTRITION, Feb. 1998, at 14. Under DSHEA, "Herbal Pro-
zac" is not a permissible labeling term.
178. See Researcher Writes the A to Z of St. John's Wort, NEW ORLEANS
TIMES PICAYUNE, July 21, 1998, at D5.
179. See Toscano, supra note 100, at 165. For a discussion of the effects
of St. John's Wort, see Murray, supra note 177, at 14, and Nash, supra note
177, at 80.
180. Brody, supra note 166, at D7.
181. Heusel, supra note 20, at 163; Mitka, supra note 152, at 1555.
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medical questions are left unanswered concerning the safety and effi-
cacy of long-term use. While athletes take Androstenedione. to im-
prove their athletic performance,' 82 there is no proof of its effective-
ness in this regard. 83 Additionally, scientists do not know how much
Androstenedione is converted into steroids, how much is absorbed by
the body, or whether it causes liver cancer and heart disease like other
oral androgens. 184  Similarly, there are unanswered questions con-
cerning St. John's Wort. No one has determined a set dosage or
whether it is the herb alone or the combination of ingredients that
make the product useful. 85 Each brand of St. John's Wort contains
different amounts of the herb and various directions for use.186 Since
these products are not subject to any meaningful approval or substan-
tiation process, unless the government places more stringent require-
ments on them, these questions may remain unanswered and standards
will go unchecked.
187
IV. CONGRESS CREATES A UNIQUE SITUATION FOR
CONSUMERS
A. The DSHEA Is a Departure from the Current Regulatory
Scheme
With the help of Congress, anyone can walk into a health food store
182. Major League Baseball allows athletes to use Androstenedione, how-
ever, the National Football League, National Collegiate Athletic Association
and the International Olympic Committee ban its use. See Brown, supra note
23, at A3. See also Sharon Begley, The Real Scandal, NEWSWEEK, Feb. 15,
1999, at 48.
183. See Endocrine Society Alert, supra note 172.
184. See id.
185. See, e.g., Efforts Under Way to Prove Herbal Supplements Work,
OMAHA WORLD, Oct. 23, 1998, at 7 [herinafter Effects Under Way]
186. See Heusel, supra note 166, at 166-67.
187. The New Jersey Assembly proposed a law that bans the sale of An-
drostenedione to persons under age 18 but the Assembly session ended be-
fore the bill was passed. See Bob Groves, Nutritional Supplement Restriction
Sought, BERGEN RECORD (New Jersey), Sept. 15, 1998, at A3. A similar bill
was introduced in December 1999 and referred to the Committee on Health.
See AB 44, 209th Leg. (N.J. 1999).
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and purchase products which have effects on the human body similar
to many prescription drugs. Consumers are buying and using more of
these products1 88 and the risks associated with them are increasing.
Although these products clearly indicate that the FDA has not con-
ducted evaluations, and the products do not make express disease-
related claims, 8 9 many manufacturers try to imply therapeutic benefit.
Further, many manufacturers successfully word claims so that they fall
within the DSHEA's regulatory safe harbors, thereby avoiding the
need to clearly demonstrate the safety and efficacy of their products.
Although the FDA controls these products, it does not do so to the
extent that many consumers might expect. Unlike vitamins, the long
and short-term health consequences that may result from the use of
these unproven remedies are not known by scientists. 190 Congress cre-
ated an atmosphere encouraging consumers to use dietary supple-
ments, but failed to provide a meaningful, working mechanism for the
FDA to ensure consumers' safety and efficacy expectations. The tools
the DSHEA gives the FDA to protect the public are less efficient than
those it takes away. Consumers can now educate themselves from a
variety of sources. For example, the World Wide Web has hundreds of
sites dedicated to alternative medicines.' 9' The Internet, however, is
notorious for giving veiled advice in the form of advertisements.
192
Television programs or book stores often cause similar problems for
consumers.1
9 3
188. In the United States, consumers spend approximately $10 to $12 bil-
lion annually on various forms of dietary supplements. See Jill Ellis, abstract
of Panel Discussion, in NIH Research Workshop, supra note 5.
189. See Heusel, supra note 20, at 162. See also Dietary Supplement
Health Education Act of 1994, Pub. L. No. 103-417, § 6(c), 108 Stat. 4325
(1994).
190. See Lise Alschuler, et al, Herbal Medicine: What Works, What's
Safe, PATIENT CARE, Oct. 15, 1997, No. 16, vol. 31, at 49.
191. See, e.g., HealthWorld's Online Herbal Medicine section (visited
Oct. 20, 1998) <http://www.healthy.net/clinin/therapy/herbal/index.html>;
U.S. FDA Dietary Supplement Information Page (visited Oct. 20, 1998)
<http://vm.cfsan.fda.gov/-dms/supplmnt.html>; The U.S. Pharmacopoeia
(visited Oct. 20, 1998) <http://www.usp.org/mgraphs/botanica>.
192. See Heusel, supra note 166, at 166.
193. See, e.g., Varro E. Tyler, THE HONEST HERBAL (1998); Varro E. Ty-
ler, HERBS OF CHOICE (1999); Andrea Peirce, AMERICAN PHARMACEUTICAL
20001
494 Journal of Contemporary Health Law and Policy [Vol. 16:463
In enacting the DSHEA, Congress departed from the FDA's regu-
latory path for controlling dietary supplements. 94 Congress reasoned
the interests of the public would be better served through less regula-
tion of dietary supplements. The DSHEA represented a significant
change in the FDA's authority over a product.195 After the FDA spent
years trying to develop greater controls over vitamins and herbs
through regulations and enforcement, 196 the DSHEA created an en-
tirely new way of looking at dietary supplements.
B. Information and Advertising Concerns
The FDA must balance the interests of the consumers and the inter-
ests of the dietary supplement manufacturers. Because consumers pos-
sess a desire for dietary supplements, 197 a means for disseminating re-
liable information must be created. The DSHEA no longer prohibits
the marketing of information or studies about a dietary supplement in
stores that carry the product.' 98 The statute does not consider publica-
tions, articles and other sources as labeling, so long as these sources
are printed in their entirety and
(1) [the source] is not false or misleading;
(2) does not promote a particular manufacturer or brand
of dietary supplements;
(3) is displayed or presented, or is displayed or pre-
sented with other such items on the same subject mat-
ter, so as to present a balanced view of the available
scientific information on a dietary supplement;
ASSOCIATION PRACTICAL GUIDE TO NATURAL MEDICINES (1998).
194. As one commentator noted, "DSHEA was passed without people re-
alizing what the significance would be in terms of tying the FDA's hands."
Porter, supra note 158, at 12 (quoting Virginia Buchanan, plaintiff's attorney
in a suit against a supplement containing ephedrine.).
195. See Fred Degnan, Dietary Supplements, § 6 The Passage of DSHEA
(on file with author).
196. See supra Part I1.A. and accompanying notes.
197. Alternative medicine advocate Andrew Weil recognizes the con-
sumer's desire for these products: "I think that there is a deep suspicion that
pharmaceutical medicine is dangerous, and people have a very great longing
for treatments hat are more natural and gentler." Herbal Rx: The Promises and
Pitfalls, CONSUMER REP., Mar. 1999, at 46 [hereinafter Herbal Rx].
198. See Young & Bass, supra note 145, at 288.
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(4) if displayed in an establishment, is physically sepa-
rate from the supplements; and
(5) does not have appended to it any information by
sticker or other method. 99
The FDA also recently issued guidelines requiring "supplemental
facts" panels to be placed on dietary supplements. 200 These panels are
similar to the "nutritional facts" panels required under the NLEA. 0
There is, however, still very little guidance concerning permissible
claims.
The FTC is responsible for monitoring and creating standards on
claims made to consumers through advertising.20 2 The FTC identifies
two challenges they have in dealing with dietary supplements.0 3 They
are educating the industry about their legal obligations and creating a
workable policy to "police the more unscrupulous members of [the
dietary supplement] industry." 204 The DSHEA created many questions
regarding the FTC's approach to dietary supplements.2 5
In response, the FTC issued a policy statement outlining the appli-
199. 21 U.S.C. § 343-2(a) (1994).
200. See 61 Fed. Reg. 49826, 49849 (1997) (to be codified at 21 C.F.R. §
103.36); see also The Selling of Supplements: Trust Me it Works, CONSUMER
REP., Mar. 1999, at 48 [herinafter The Selling of Supplements]. These labels
will make it easier for the consumer to compare products, but the labels do
not claim to certify the exact percentage of ingredients in the product. See id.
201. See Food Labeling; Statement of Identity, Nutrition Labeling and In-
gredient Labeling of Dietary Supplements; Compliance Policy Guide, Revo-
cation, 62 Fed. Reg. 49826 (1997); Food Labeling; Requirement for Nutrient
Content Claims, Health Claims and Statement of Nutritional Support for
Dietary Supplements, 62 Fed. Reg. 49859, 49865 (1997).
'202. See 15 U.S.C. § 52 (1998). "It shall be unlawful.., to disseminate,
or cause to be disseminated, any false advertisement ... [with] the purpose
of inducing, or which is likely to induce, directly or indirectly the purchase
of foods, drugs, devices, services, or cosmetics." Id.
203. See Jodie Bernstein, Director, Bureau of Consumer Protection, "FTC
and Dietary Supplements" FDLI Conference on Substantiating Claims for
Dietary Supplement Advertising and Labeling, Nov. 13, 1997 (visited July 26,
1999) <http://www.ftc.gov/speeches/other/jodie2.htm>.
204. Id.
205. See Dietary Supplements: An Advertising Guide for Industry, (vis-
ited July 26, 1999) <http://www.ftc.gov/bcp/conline/pubs/buspubs/dietsupp.
htm>.
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cation of FTC law to dietary supplements.2 °6 Advertising must be
truthful, not misleading and advertisers must have adequate substan-
tiation for all objective product claims; 207 anecdotal evidence is not
enough.08 The guidelines give examples to highlight the most com-
mon violations. 20 9 Recent FTC guidelines require labeling claims to
be based on reliable scientific evidence.
210
Both agencies are trying to ensure that the public is protected.
Since the FDA has more expertise with the actual products, establish-
ing standards for determining when a claim is false or misleading is a
wise step. A joining of forces between the FDA and the FTC to de-
termine whether adequate substantiation for a claim exists would in-
crease enforcement. Heightened FTC involvement would serve as an
additional source of monitoring for the dietary supplement industry.
For example, the FTC has already taken an active role in monitoring
labels. In 1998, the FTC took action against seven manufacturers for




Although the possibility of further regulation can have immediate
negative consequences for the industry, the long-term results will




209. See id. These violations include misleading advertisements, fine
printed disclosures, claims that refer to a specific level of support such as
"scientists now agree," and claims surrounding evidence and effectiveness.
See id.
210. See The Selling of Supplements, supra note 200, at 48. See also 16
C.F.R. § 225.2(a).
211. See Jane E. Brody, Law Calls Herbs Food, Not Drugs, N.Y. TIMES,
Feb. 9, 1999, at D7. The Commission has also warned 1,200 Internet sites
that made "incredible claims" for drugs and supplements and issued adver-
tising guidelines aimed at the dietary supplement industry. See id.
212. The FTC Director of the Bureau of Consumer Protection stated that
basing claims on scientific evidence will give "good players in the industry.
. the guidance they need. Others will continue to face vigorous enforcement
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conceived and supported test highlighting the effects of dietary sup-
plements, advertisers could use the evidence. Many manufacturers,
however, shy away from investing in research to show a product's
health value. Once the evidence is available, other manufacturers
would be able to tout such attributes on their label without having to
engage in any research.1 3 Not surprisingly, it is reported that only
two companies are currently testing the safety and efficacy of their
herb products.21 4 Unfortunately, these companies are the exception to
the rule. In the alternative, an industry-wide fund, would increase the
availability of clinical research. Rather than have each company
sponsor research, supplement manufacturers would pay into the fund
based on their market share.
215
Several reasons compel the dietary supplement manufacturers to
clinically test their products. First, the industry receives the benefit
from marketing products. Second, manufacturers have the resources
for this funding. Third, neither the FDA nor the Office of Dietary
Supplements at the National Institutes of Health, which was created by
the DSHEA, has the funding to research all of the products that need
to be tested.21 6 Fourth, even limited safety and efficacy tests could be
used for a variety of helpful purposes such as: helping to satisfy FTC
advertising regulations, attaining the DSHEA goal of presenting bal-
by the FTC." The Selling of Supplements, supra note 200, at 48.
213. See id.
214. See Efforts Under Way, supra note 185, at 7. A third company,
PharmaPrint of Irvine, California had stated an interest in asking the FDA to
approve its herbal supplements as drugs. See Herbal Rx, supra note 197, at
48.
215. See Michael Higgins, Hard to Swallow, 85 A.B.A. J. 63 (June 1999).
Bruce Silverglade of the Center for Science in the Public Interest says mem-
bers of his group have talked about the idea but nothing has "gotten off the
ground yet." Id.
216. See NIH Research Workshop, supra note 5, at 2; see also Jane E.
Brody, Trying to Evaluate Effectiveness, N.Y. TIMES, Feb. 9, 1999, at D7.
The Office of Dietary Supplements is currently helping to finance a three-
year multi-center study of St. John's Wort as a treatment for clinical depres-
sion. See id. Sadly, the FDA spends three times more resources monitoring
drugs for pet and farm animals than it does for dietary supplements. See
Thomas J. Moore, Messing with Mother Nature, WASHINGTONIAN, July
1999, at 59.
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anced information to the consumer concerning the biological effects of
the products, and assuring consumers steps are taken to systematically
consider the safety and reliability of supplement products.217
D. Standardization of Dietary Supplements
One of the few powers the DSHEA gave the FDA was the authority
to require "good manufacturing practices. '2 s18 FDA standards specify
factory conditions but do not guarantee the efficacy or purity of the
products. 219 These standards ensure only that all products are handled
and made the same way and that sanitary practices are followed.22 ° In
February 1997, the FDA published an Advance Notice of Proposed
Rulemaking and requested comments on manufacturing practices for
22 222dietary supplements.221 To date, no further action has been taken.
The lack of standardization of supplement ingredients has had ad-
verse effects on consumers, including death.223 Companies are allowed
to promote the effectiveness of their products, but at the same time are
not required to provide expansive health warnings. A study of the
most popular brands of St. John's Wort showed a significant discrep-
217. There are a number of completed studies abroad. For example, Ger-
many's Commission E has approved 254 botanicals as safe and reasonably
effective and found 126 ineffective, unsafe or both. See Brody, supra note
216, at D7.
218. Dietary Supplement Health Education Act of 1994, Pub. L. No. 103-
417 § 402(g) (codified at 21 U.S.C. § 342(g) (1994)).
219. See id. There have been dangerous instances concerning supplements
that lack purity. See, e.g., Jim Ritter, Herbal Warning: Concerns Raised
About Quality of Supplements, CHI. SUN TIMES, Oct. 13, 1998, at 1.
220. See Dietary Supplement Health Education Act of 1994, Pub. L. No.
103-417 § 402(g)(2) (codified at 21 U.S.C. § 342(g)(2)). These regulations
must be modeled after comparable food regulations. See id.
221. See Current Good Manufacturing Practice in Manufacturing, Packing
or Holding Dietary Supplements, 62 Fed. Reg. 24,619 (1997) (proposed Feb.
6, 1997).
222. See Henney, supra note 9, at 8 (Commissioner Henney stated that
although the agency has not moved rapidly on this topic, it is now considered
a high priority).
223. See NIH Research Workshop, supra note 5, at 3; see also Okie, su-
pra note 139, at 77.
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ancy between the actual and claimed amount of St. John's Wort in the
product.224 As a result, some consumers are purchasing products that
are much stronger than desired, while others are buying no more than
a very expensive placebo.225
Set standards for quality, strength and purity can help solve some of
the problems with dietary supplements. To fully address these prob-
lems, safety and labeling authority that DSHEA does not provide for,
and in fact, was expressly taken away is needed.
CONCLUSION
The DSHEA deviates from the direction in which food and drug law
had been headed this century. Consumers are unknowingly taking their
health into their own hands through the use of dietary supplements.
Although the DSHEA proposes to protect the consumer, it actually
works against the FDA's ability to do so. Until the dietary supplement
industry can offer the assurance that it can fill that role, consumers
risk misinformation as well as physical harm. In many instances, die-
tary supplements are as potent as prescription drugs, yet the FDA can
only prosecute manufacturers for mislabeling a product or clearly
making health-related claims. Under the DSHEA, the FDA retains the
authority to investigate claims relating to dietary supplements. This
authority, in the context of a joint regulatory scheme with the FTC,
could result in greater enforcement ability. A coordinated effort be-
tween the government and industry could one day bring about the de-
gree of safety that consumers have come to expect.
224. See Heusel, supra note 166, at 166.
225. See Heusel, supra note 20, at 162.
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